GILD
Gilead Sciences, Inc.
GILD has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over GILD overall, supported by stronger fundamentals and stronger modeled upside.
GILD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Strong | |
| Healthy |
GILD's cash flow and balance sheet are currently healthy, and its revenue is stable, but its profitability is weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
GILD PE Valuation
GILD has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 20x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
GILD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect GILD to return to profit, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
GILD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.55 | — |
| Q3 2026 | -$3.15 | -149% |
| Q2 2026 | -$2.66 | -153% |
| Q1 2026 | $7.35 | +54% |
| Q4 2025 | $6.78 | +1684% |
| Q3 2025 | $6.46 | +7078% |
| Q2 2025 | $5.03 | +513% |
| Q1 2025 | $4.76 | +1222% |
| Q4 2024 | $0.38 | -92% |
GILD has swung to a loss: it lost $3.15 per share over the past year, after a profit the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over GILD on earnings quality, reporting a profit while its opponent remains loss making.
GILD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8.3B | +6.8% |
| Q2 2026 | $7.8B | +10% |
| Q1 2026 | $7B | +4.4% |
| Q4 2025 | $7.9B | +4.7% |
| Q3 2025 | $7.8B | +3% |
| Q2 2025 | $7.1B | +1.8% |
| Q1 2025 | $6.7B | -0.3% |
| Q4 2024 | $7.6B | +6.4% |
GILD's revenue has grown year over year for six quarters in a row: $8.3B last quarter, up 6.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 42% | -1.1 points |
| Q2 2026 | -133% | -168 points |
| Q1 2026 | 37% | +3.6 points |
| Q4 2025 | 25% | -7.4 points |
| Q3 2025 | 43% | +31 points |
| Q2 2025 | 35% | -3.1 points |
| Q1 2025 | 34% | +98 points |
| Q4 2024 | 32% | +9.7 points |
GILD has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over GILD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
GILD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.8B | +21% |
| Q2 2026 | $3.4B | +377% |
| Q1 2026 | $2.4B | +47% |
| Q4 2025 | $3.1B | +10% |
| Q3 2025 | $4B | -5% |
| Q2 2025 | $720M | -40% |
| Q1 2025 | $1.7B | -22% |
| Q4 2024 | $2.8B | +45% |
GILD's free cash flow has been positive every quarter for seven years: $13.8B over the past year, up 50% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over GILD on cash flow, with more consistent year-over-year improvement.
GILD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +8M shares |
| 1 year | -0.2% | -3M shares |
| 3 years | -0.5% | -6M shares |
| 5 years | -0.9% | -11M shares |
| Available history | -2% | -26M shares |
GILD has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $370M |
| Q2 2026 | $355M |
| Q1 2026 | $419M |
| Q4 2025 | $230M |
| Q3 2025 | $435M |
| Q2 2025 | $527M |
| Q1 2025 | $730M |
| Q4 2024 | $350M |
GILD spent $1.4B buying back its own shares over the past year, down 33% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
GILD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 1.4x | Healthy |
| Q4 2025 | 1.7x | Healthy |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 2.4x | Moderate |
| Q1 2025 | 2.0x | Healthy |
| Q4 2024 | 8.2x | High |
| Q3 2024 | 10.1x | High |
| Q2 2024 | 5.0x | High |
GILD's net debt is about 1.4 years of its operating earnings (EBITDA), down from 2.0 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
GILD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.7 | Neutral |
| Stochastic | 83.3 | Overbought |
GILD's weekly RSI is 69 (neutral) and its Stochastic is 83 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
GILD PE vs Healthcare Sector
| Metric | GILD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
GILD has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
GILD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $158.1 | 6.3% above |
| 20 week MA | $146.4 | 15% above |
| 50 week MA | $138.9 | 21% above |
| 100 week MA | $124.2 | 35% above |
| 200 week MA | $101.1 | 66% above |
GILD is in an uptrend: it's above all five of its weekly moving averages, and 66% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
GILD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $66.0 | $57.1 | -13% |
| 2021 | $57.1 | $72.5 | +27% |
| 2022 | $72.5 | $84.8 | +17% |
| 2023 | $84.8 | $81.0 | -4.4% |
| 2024 | $81.0 | $94.1 | +16% |
| 2025 | $94.1 | $124.7 | +33% |
| 2026 YTD | $124.7 | $168.0 | +35% |
GILD has finished higher in four of the last six years. It's up 35% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over GILD on returns for 2026, with the stronger performance.